Heart disease; Cardiovascular disease; Diseases of the osteoarticular system; Pituitary diseases; Endocrinopathy; Endocrinology; Human; Heart failure; Prognosis; Long term; Acromegaly; Cardiopathie; Appareil circulatoire pathologie; Système ostéoarticulaire pathologie; Hypophyse pathologie; Endocrinopathie; Endocrinologie; Homme; Insuffisance cardiaque; Pronostic; Long terme; Acromégalie
Abstract :
[en] Cardiovascular complications are a major cause of morbidity and mortality in patients with acromegaly. Normalization of GH secretion is associated with an improvement in structural and functional cardiac abnormalities. However, the long-term cardiac effects of treatment for acromegaly have not been studied in patients who have already developed chronic congestive heart failure (CHF). We reviewed the charts of 330 consecutive patients with acromegaly treated in two French and Belgian centers since 1985. Ten patients with both acromegaly and CHF (eight men, two women, mean age 49.7 yr) were studied retrospectively. One of them was excluded because CHF was due to severe aortic stenosis. CHF ( New York Heart Association stages III-IV and echocardiography showing dilated hypokinetic cardiomyopathy with left ventricular systolic dysfunction and a left ventricular ejection fraction less than 45%) was diagnosed before, concomitantly, or after acromegaly in, respectively, two, five, and two patients. Three patients were referred with terminal heart failure requiring transplantation. One patient had transient CHF associated with a hypertensive crisis. The other eight patients had symptomatic chronic CHF. Control of GH hypersecretion failed, totally or partially, in three patients: one had a long-term survival, and the two others died at 1 and 5 yr. Good GH control was achieved in five patients: four of these are still alive 2-16 yr after diagnosis of CHF, their clinical status is stable or improved, and their quality of life is good. Overall, the 1- and 5-yr mortality ( or transplantation) rates for patients with chronic symptomatic CHF were 25% ( 2 of 8 patients) and 37.5% ( 3 of 8 patients), respectively. In conclusion, less than 3% of acromegalic patients developed CHF in this study. Although effective treatment of acromegaly improved short-term cardiovascular status, its impact on long-term survival is questionable.
Bates AS, Van't Hoff W, Jones JM, Clayton RN 1993 An audit of outcome of treatment in acromegaly. Q J Med 86:293-299
McGuffin Jr WL, Sherman BM, Roth F, Gorden P, Kahn CR, Roberts WC, Frommer PL 1974 Acromegaly and cardiovascular disorders. A prospective study. Ann Intern Med 81:11-18
Sacca L, Cittadini A, Fazio S 1994 Growth hormone and the heart. Endocr Rev 15:555-573
Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P, Petretta M, Tamburrano G, Lombardi G, Liuzzi A 2000 Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab 85:193-199
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Florimonte L, Salvatore M, Lombardi G 1999 Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly. J Clin Endocrinol Metab 84:17-23
Colao A, Cuocolo A, Marzullo P, Nicolai E, Ferone D, Della Morte AM, Pivonello R, Salvatore M, Lombardi G 2001 Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. J Clin Endocrinol Metab 86:1551-1557
Colao A, Marzullo P, Cuocolo A, Spinelli L, Pivonello R, Bonaduce D, Salvatore M, Lombardi G 2003 Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide. Clin Endocrinol (Oxf) 58:169-176
Hradec J, Kral J, Janota T, Krsek M, Hana V, Marek J, Malik M 1999 Regression of acromegalic left ventricular hypertrophy after lanreotide (a slow-release somatostatin analog). Am J Cardiol 83:1506-1509, A8
Damjanovic SS, Neskovic AN, Petakov MS, Popovic V, Vujisic B, Petrovic M, Nikolic-Djurovic M, Simic M, Pekic S, Marinkovic J 2002 High output heart failure in patients with newly diagnosed acromegaly. Am J Med 112: 610-616
Hayward RP, Emanuel RW, Nabarro JD 1987 Acromegalic heart disease: influence of treatment of the acromegaly on the heart. Q J Med 62:41-58
Chanson P, Timsit J, Masquet C, Warnet A, Guillausseau PJ, Birman P, Harris AG, Lubetzki J 1990 Cardiovascular effects of the somatostatin analog octreotide in acromegaly. Ann Intern Med 113:921-925
Legrand V, Beckers A, Pham VT, Demoulin JC, Stevenaert A 1994 Dramatic improvement of severe dilated cardiomyopathy in an acromegalic patient after treatment with octreotide and trans-sphenoidal surgery. Eur Heart J 15:1286-1289
Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S 2000 Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529
McKee PA, Castelli WP, McNamara PM, Kannel WB 1971 The natural history of congestive heart failure: the Framingham study. N Engl J Med 285:1441-1446
Remme WJ, Swedberg K 2001 Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22:1527-1560
Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT, Brosnihan B, Morgan TM, Stewart KP 2002 Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288:2144-2150
MacCarthy PA, Kearney MT, Nolan J, Lee AJ, Prescott RJ, Shah AM, Brooksby WP, Fox KA 2003 Prognosis in heart failure with preserved left ventricular systolic function: prospective cohort study. BMJ 327:78-79
Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A 2002 Guidelines for acromegaly management. J Clin Endocrinol Metab 87:4054-4058
Timsit J, Chanson P, Larger E, Duet M, Mosse A, Guillausseau PJ, Harris AG, Moulonguet M, Warnet A, Lubetzki J 1987 The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly. Acta Endocrinol (Copenh) 116: 108-112
Sahn DJ, DeMaria A, Kisslo J, Weyman A 1978 Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072-1083
Savage DD, Henry WL, Eastman RC, Borer JS, Gorden P 1979 Echocardiographic assessment of cardiac anatomy and function in acromegalic patients. Am J Med 67:823-829
Scanu P, Grollier G, Commeau P, Lamy E, Foucault J, Potier J 1985 [Cardiac failure in acromegaly. A propos d'un cas]. Ann Med Intern (Paris) 16:663-666 (French)
Ezzat S, Forster MJ, Berchtold P, Redelmeier DA, Boerlin V, Harris AG 1994 Acromegaly. Clinical and biochemical features in 500 patients. Medicine 73: 233-240
Sacca L, Napoli R, Cittadini A 2003 Growth hormone, acromegaly, and heart failure: an intricate triangulation. Clin Endocrinol (Oxf) 59:660-671
Timsit J, Riou B, Bertherat J, Wisnewsky C, Kato NS, Weisberg AS, Lubetzki J, Lecarpentier Y, Winegrad S, Mercadier JJ 1990 Effects of chronic growth hormone hypersecretion on intrinsic contractility, energetics, isomyosin pattern, and myosin adenosine triphosphatase activity of rat left ventricle. J Clin Invest 86:507-515
Peterson ME, Taylor RS, Greco DS, Nelson RW, Randolph JF, Foodman MS, Moroff SD, Morrison SA, Lothrop CD 1990 Acromegaly in 14 cats. J Vet Int Med 4:192-201
Wang TJ, Levy D, Benjamin EJ, Vasan RS 2003 The epidemiology of "asymptomatic" left ventricular systolic dysfunction: implications for screening. Ann Intern Med 138:907-916
Levy D, Kenchaiah S, Larson MG, Benjamin EJ, Kupka MJ, Ho KK, Murabito JM, Vasan RS 2002 Long-term trends in the incidence of and survival with heart failure. N Engl J Med 347:1397-1402
Jessup M, Brozena S 2003 Heart failure. N Engl J Med 348:2007-2018
Lim MJ, Barkan AL, Buda AJ 1992 Rapid reduction of left ventricular hypertrophy in acromegaly after suppression of growth hormone hypersecretion. Ann Intern Med 117:719-726
Lopez-Velasco R, Escobar-Morreale HF, Vega B, Villa E, Sancho JM, Moya-Mur JL, Garcia-Robles R 1997 Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 82:1047-1053
Merola B, Cittadini A, Colao A, Ferone D, Fazio S, Sabatini D, Biondi B, Sacca L, Lombardi G 1993 Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 77:790-793
Pereira JL, Rodriguez-Puias MJ, Leal-Cerro A, Martinez A, Garcia-Luna PP, Gavilan I, Pumar A, Astorga R 1991 Acromegalic cardiopathy improves after treatment with increasing doses of octreotide. J Endocrinol Invest 14:17-23
Hradec J, Marek J, Kral J, Janota T, Poloniecki J, Malik M 1993 Long-term echocardiographic follow-up of acromegalic heart disease. Am J Cardiol 72: 205-210
Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G 2000 Cardiovascular effects of depot long-acting somatostatin analog Sandostarin LAR in acromegaly. J Clin Endocrinol Metab 85:3132-3140
Giustina A, Boni E, Romanelli G, Grassi V, Giustina G 1995 Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide. Am J Cardiol 75:1042-1047
Lie JT 1980 Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients. Am Heart J 100:41-52
Lombardi G, Colao A, Marzullo P, Biondi B, Palmieri E, Fazio S 2002 Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 25:971-976
Manelli F, Desenzani P, Boni E, Bugari G, Negrini F, Romanelli G, Grassi V, Giustina A 1999 Cardiovascular effects of a single slow release injection in patients with acromegaly and left ventricular hypertrophy. Pituitary 2:205-210
Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S 2003 Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242-1247
Chanson P 2001 Impact of growth hormone-lowering treatments on heart function in acromegaly. In: Giustina A, ed. Growth hormone and the heart. Boston: Kluwer Academic Publishers; 45-57
Cohn JN, Ferrari R, Sharpe N 2000 Cardiac remodeling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. On behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol 35:569-582
Pitt D 1995 ACE inhibitor cotherapy in patients with heart failure: rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J 16(Suppl N):107-110
1987 Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 316:1429-1435
1991 Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 325:293-302
Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW 1998 Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 32:695-703
